Cargando…

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine

BACKGROUND: To date, only a few studies reported data regarding the development of mucosal immune response after the BNT162b2-booster vaccination. METHODS: Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose (T3) and after two weeks (T4). Anti-S1-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azzi, Lorenzo, Dalla Gasperina, Daniela, Veronesi, Giovanni, Shallak, Mariam, Maurino, Vittorio, Baj, Andreina, Gianfagna, Francesco, Cavallo, Pierpaolo, Dentali, Francesco, Tettamanti, Lucia, Maggi, Fabrizio, Maffioli, Lorenzo Stefano, Tagliabue, Angelo, Accolla, Roberto Sergio, Forlani, Greta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828819/ https://www.ncbi.nlm.nih.gov/pubmed/36628844 http://dx.doi.org/10.1016/j.ebiom.2022.104435

Ejemplares similares

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Reply to the Letter to the Editor: “Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 vaccine” by Francavilla B et al.: Lack of a strong oral mucosal immune response: rethinking the route of COVID-19 vaccine boost administration?
por: Azzi, Lorenzo, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Saliva is a reliable tool to detect SARS-CoV-2
por: Azzi, Lorenzo, et al.
Publicado: (2020)

Safety and immunogenicity of synchronous COVID19 and influenza vaccination
por: Baj, Andreina, et al.
Publicado: (2022)

Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells
por: Forlani, Greta, et al.
Publicado: (2020)

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects
por: Spezia, Pietro Giorgio, et al.
Publicado: (2022)

Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study
por: Azzi, Lorenzo, et al.
Publicado: (2020)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution
por: Baj, Andreina, et al.
Publicado: (2021)

Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1
por: Forlani, Greta, et al.
Publicado: (2019)

HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models
por: Forlani, Greta, et al.
Publicado: (2021)

The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy
por: Forlani, Greta, et al.
Publicado: (2023)

Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia
por: Forlani, Greta, et al.
Publicado: (2021)

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
por: Baj, Andreina, et al.
Publicado: (2021)

Pilot Study: Long-Term Shedding of SARS-CoV-2 in Urine: A Threat for Dispersal in Wastewater
por: Baj, Andreina, et al.
Publicado: (2020)

Anti-SARS-CoV-2 antibody levels and kinetics of vaccine response: potential role for unresolved inflammation following recovery from SARS-CoV-2 infection
por: Gianfagna, F., et al.
Publicado: (2022)

Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA
por: Celesti, Fabrizio, et al.
Publicado: (2023)

The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing
por: Shallak, Mariam, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Time Trends of Percutaneous Injuries in Hospital Nurses: Evidence of the Interference between Effects of Adoption of Safety Devices and Organizational Factors
por: Ferrario, Marco M., et al.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses
por: Forlani, Greta, et al.
Publicado: (2017)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
por: Li, Rui, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases
por: Baratella, Marco, et al.
Publicado: (2017)

Blastomycosis of the psoas muscles
por: Ietto, Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s863bo7prfopbg8qm9oelor3j0